top of page
Browse by category
Search
Novo Nordisk lowers cost of Ozempic to $499 per month for self-paying patients
Novo Nordisk has launched a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved...
Ozempic may weaken muscles even as muscle size remains stable
A study in mice by researchers at the University of Utah Health Sciences suggests that muscle mass changes less than expected, but...
The Obesity Society commends FDA's resolution of obesity drug shortages and calls for enforcement against unauthorised compounding
The Obesity Society (TOS) has acknowledged the FDA’s recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and...
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
European Medicines Agency to discuss anaesthesia risk for weight-loss drugs
The European Medicines Agency (EMA) will assess the risk that patients on weight loss drugs such as semaglutide and tirzepatide may...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
Browse by tag
bottom of page